Filing Flows › Companies › Maze Therapeutics › Cash flow
Maze Therapeutics cash flow, quarter by quarter
Latest: Q2 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$15.2M in Q2 2026 · −$107M over twelve months
Analysis
In Q2 2026, Maze Therapeutics generated −$15.1M of operating cash flow and spent $107K on capital projects, leaving free cash flow of −$15.2M. That is $15.3M more than in Q2 2025 (−$30.4M).
Over the twelve months to Jun 30, 2026, operating cash flow was −$107M; the largest uses were other investing ($292M), operating cash flow ($107M), capital spending ($302K); besides operations, cash came from other financing ($326M), shares issued ($11.2M); the cash balance fell by $61.9M.
Operating cash flow was −$15.1M against net income of −$44.7M. The largest differences: stock-based pay +$9.2M, accrued liabilities +$4.0M, prepaid and other assets −$1.9M.
Free cash flow
Where the cash came from and went
From profit to cash
Every quarter
| Quarter | Operating cash flow | Capital spending | Net borrowing (+) / repaid (−) | Shares issued | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|---|---|
| Q2 2026 | −$15.1M | −$107K | — | $1.7M | −$3.9M | −$15.2M |
| Q1 2026 | −$39.1M | −$93K | $39.4M | $4.1M | −$9.5M | −$39.2M |
| Q4 2025 | −$27.7M | −$34K | — | $3.4M | $128M | −$27.8M |
| Q3 2025 | −$24.6M | −$68K | — | −$439K | −$52.2M | −$24.7M |
| Q2 2025 | −$30.1M | −$393K | — | $2.4M | $29.8M | −$30.4M |
| Q1 2025 | −$29.5M | −$299K | — | $128M | −$97.6M | −$29.8M |
| Q4 2024 | −$22.5M | −$605K | — | $63K | −$47.2M | −$23.1M |
| Q3 2024 | −$23.2M | −$103K | — | $226K | $25.5M | −$23.3M |
Maze Therapeutics: income statement and cash flow
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%. The chart follows the revenue to costs, profit and cash.
Maze Therapeutics: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.